Sandra Leung Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 5 days, 8 hours ago
Sandra Leung has an estimated net worth of at least $28.4 million*, as of July 16, 2025. They own 457,732 shares of BMY stock. They have sold 94,390 shares of BMY stock since 2021, for an estimated $6.9 million.
Sandra Leung $BMY SEC Form 4 Insider Trading
Sandra Leung has filed a total of 2 insider trades in $BMY since 2021. Their most recent trade was a sale of 65,000 shares, made on Jun 06, 2022. Their largest trade was a sale of 65,000 shares, made on Jun 06, 2022. We estimate that they now own 457,732 shares of $BMY, worth an estimated $21.5 million.
Insider Trading at $BMY
There have been a total of 43 insider trades reported at $BMY since 2021, with 23,474 shares purchased and 1.3 million shares sold. The most active insider traders in $BMY stock have been Giovanni Caforio, Rupert Vessey, and Ann Powell. The most recent trade was a sale of 97 shares reported by Benjamin Hickey (President, RayzeBio Org.), made on May 09, 2025.
History of Insider Stock Trades by Sandra Leung
$BMY Executives and Stock Owners with Insider Trades
-
Giovanni Caforio, Board Chair and CEO
-
Rupert Vessey, EVP, Research & Early Dev.
-
Ann Powell, EVP, Chief Human Resources
-
Autenried Paul Von, EVP, Chief Information Officer
-
David V Elkins, EVP, Chief Financial Officer
-
Christopher S. Boerner, Chief Executive Officer
-
Samit Hirawat, EVP,Chief Med.Offr.,Drug Dev.
-
Sandra Leung, EVP, General Counsel
-
Adam Dubow, SVP,ChiefCompliance&EthicsOff.
-
Benjamin Hickey, President, RayzeBio Org.
-
Christopher S. Boerner, EVP, Chief Commercial Officer
-
Giovanni Caforio, Chairman and CEO
-
Karen Murphy Santiago, SVP & Controller
-
Phil M Holzer, SVP and Controller
-
Rupert Vessey, EVP & President, Research
-
Robert M Plenge, EVP, Chief Research Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.